IDENTIFICATION AND TARGETING OF TUMOR DRIVER SCHWANN(NF2LOSS) CELLS IN SPORADIC AND NF2-RELATED VESTIBULAR SCHWANNOMAS

被引:0
|
作者
Laws, Maxwell [1 ]
Asuzu, David [1 ]
Rampalli, Ihika [1 ]
Mullaney, Dustin [1 ]
Laraba, Liyam [2 ]
Mandel, Debjani [1 ]
Zhang, Xiyuan [3 ]
Elkahloun, Abdel [4 ]
Sisay, Bayu [4 ]
Maric, Dragan [5 ]
Johnson, Kory [6 ]
Abdullaev, Zied [7 ]
Aldape, Kenneth [7 ]
Shern, John [3 ]
Parkinson, David [2 ]
Chittiboina, Prashant [1 ]
机构
[1] Natl Inst Neurol Disorders & Stroke, NIH, Surg Neurol Branch, Bethesda, MD USA
[2] Plymouth Univ, Sch Med & Dent, Plymouth, England
[3] NCI, NIH, Ctr Canc Res, Pediat Oncol Branch,Tumor Evolut & Genom Sect, Bethesda, MD USA
[4] Natl Human Genome Res Inst, NIH, Canc Genet & Comparat Genom Branch, Bethesda, MD USA
[5] Natl Inst Neurol Disorders & Stroke, NIH, Flow & Imaging Cytometry Core Facil, Bethesda, MD USA
[6] Natl Inst Neurol Disorders & Stroke, NIH, DIR Bioinformat Sect, Bethesda, MD USA
[7] NCI, NIH, Lab Pathol, Bethesda, MD USA
关键词
D O I
10.1093/neuonc/noae165.0268
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CSIG-19
引用
收藏
页数:1
相关论文
共 50 条
  • [41] Clinical severity grading of NF2-related schwannomatosis
    McLean, Anna C. Lawson
    Loeschner, Denise
    Farschtschi, Said
    Dengler, Nora F.
    Rosahl, Steffen K.
    ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)
  • [42] Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma
    Phioanh Leia Nghiemphu
    Jeremie Vitte
    Eva Dombi
    Thien Nguyen
    Naveed Wagle
    Akira Ishiyama
    Ali R. Sepahdari
    David Cachia
    Brigitte C. Widemann
    Derald E. Brackmann
    Joni K. Doherty
    Michel Kalamarides
    Marco Giovannini
    Journal of Neuro-Oncology, 2024, 167 : 339 - 348
  • [43] THE ANALYSIS OF NF2 GENE MUTATION IN SPORADIC SCHWANNOMAS
    卞留贯
    孙青芳
    沈建康
    赵卫国
    罗其中
    Journal of Shanghai Second Medical University, 2002, (01) : 30 - 36
  • [44] Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma
    Nghiemphu, Phioanh Leia
    Vitte, Jeremie
    Dombi, Eva
    Nguyen, Thien
    Wagle, Naveed
    Ishiyama, Akira
    Sepahdari, Ali R.
    Cachia, David
    Widemann, Brigitte C.
    Brackmann, Derald E.
    Doherty, Joni K.
    Kalamarides, Michel
    Giovannini, Marco
    JOURNAL OF NEURO-ONCOLOGY, 2024, 167 (02) : 339 - 348
  • [45] NF2-RELATED SCHWANNOMATOSIS - AN ATYPICAL CASE PRESENTATION
    Soares, Marta P.
    Brito, Isabel
    Passos, Joao
    Carvalho, Joao
    Lima, Jorge
    Santos, Filipa Baptista
    Dupont, Juliette
    Sousa, Ana Berta
    MEDICINE, 2023, 102 (13)
  • [46] Vestibular dysfunction in NF2-related schwannomatosis (vol 5, facd089, 2023)
    Madhani, Amsal S.
    BRAIN COMMUNICATIONS, 2023, 5 (03)
  • [47] Loss of merlin-p85 protein complex in NF2-related tumors
    Takeshima, H
    Nishi, T
    Yamamoto, K
    Kino, T
    Nakamura, H
    Saya, H
    Kochi, M
    Kuratsu, JI
    Ushio, Y
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 12 (05) : 1073 - 1078
  • [48] B CLINICAL SEVERITY GRADING OF NF2-RELATED SCHWANNOMATOSIS
    McLean, A. Lawson
    Loeschner, D.
    Farschtschi, S.
    Dengler, N.
    Neumeister, A.
    Senft, C.
    Rosahl, S.
    NEURO-ONCOLOGY, 2024, 26 : V118 - V118
  • [49] NF2-related Schwannomatosis: an updated epidemiological study.
    Forde, Claire
    Smith, Miriam
    Burghel, George
    Bowers, Naomi
    Roberts, Nicola
    Lavin, Tim
    Halliday, Jane
    King, Andrew
    Rutherford, Scott
    Pathmanaban, Omar
    Lloyd, Simon
    Freeman, Simon
    Halliday, Dorothy
    Axon, Patrick
    Buttimore, Juliette
    Afridi, Shazia
    Laitt, Roger
    Thomas, Owen
    Evans, D. Gareth
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 1734 - 1734
  • [50] Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis
    Lu, Simeng
    Yin, Zhenzhen
    Chen, Jie
    Wu, Limeng
    Sun, Yao
    Gao, Xing
    Huang, Peigen
    Jordan, Justin T.
    Plotkin, Scott R.
    Xu, Lei
    CANCERS, 2024, 16 (11)